CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 3, 2012--
Verastem, Inc., (NASDAQ: VSTM) a biopharmaceutical company focused on
discovering and developing drugs to treat breast and other cancers by
targeting cancer stem cells (CSCs), announced that it was added to the
Russell 2000® index effective at the close of the U.S. markets on March
30, 2012.
The Russell 2000® Index, a subset of the Russell 3000® Index, measures
the performance of the small-cap segment of U.S. equities. Russell
indexes are widely used by investment managers and institutional
investors for index funds and as benchmarks for both passive and active
investment strategies.
About Verastem, Inc.
Verastem, Inc. (NASDAQ: VSTM) is a biopharmaceutical company focused on
discovering and developing drugs to treat breast and other cancers by
targeting cancer stem cells. Cancer stem cells are an underlying cause
of tumor recurrence and metastasis. For more information please visit www.verastem.com.
Forward-looking statements:
Any statements in this press release about future expectations, plans
and prospects for the Company constitute forward-looking statements
within the meaning of The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by such
forward-looking statements. The Company anticipates that subsequent
events and developments will cause the Company’s views to change.
However, while the Company may elect to update these forward-looking
statements at some point in the future, the Company specifically
disclaims any obligation to do so.
Source: Verastem, Inc.
Investor contact:
Verastem, Inc.
Brian Sullivan,
617-252-9314
bsullivan@verastem.com
or
Media
contact:
For Verastem, Inc.
Kari Watson, 781-235-3060
kwatson@macbiocom.com
